Welcome to our dedicated page for InMode Ltd. Ordinary Shares news (Ticker: INMD), a resource for investors and traders seeking the latest updates and insights on InMode Ltd. Ordinary Shares stock.
InMode Ltd. (NASDAQ: INMD) is a leading global provider of innovative medical technologies specializing in minimally and non-invasive surgical aesthetic and medical treatment solutions. The company's product portfolio spans three major energy-based treatment categories: face & body contouring, medical aesthetics, and women's health. Their products, such as BodyTite, Optimas, Votiva, Contoura, Triton, EmbraceRF, EvolveX, Evoke, EmpowerRF, and Morpheus8, are widely utilized in plastic surgery, dermatology, gynecology, and ophthalmology.
InMode’s flagship products, including Fractora for skin texture improvement, Lumecca for photorejuvenation, Diolaze for hair removal, and BodyFX for body contouring, are designed to deliver effective and exciting aesthetic solutions.
InMode has consistently invested in research and development to expand its intellectual property portfolio, which is pivotal for maintaining its competitive edge. Recently, the company initiated legal action against BTL Industries for patent infringement regarding their radio-frequency based feminine rejuvenation products.
Despite market headwinds, including higher interest rates affecting equipment financing and slower purchase decisions, InMode has shown resilience with a 2% increase in Q3 2023 revenues, totaling $123.1 million. The company also saw a 13% rise in international sales during this period.
In Q1 2024, InMode announced pre-orders for two new platforms, IgniteRF and Optimus Max, which are anticipated to drive future growth. Additionally, a new share repurchase program and the appointment of Dr. Michael Anghel as Chairman of the Board underscore the company’s commitment to shareholder value.
InMode's innovative spirit is further highlighted by their recent partnership with P1 Offshore Racing, sponsoring the only female driver, Victoria Rand, signaling a strong commitment to empowering women.
For more detailed information and the latest updates, visit InMode's official website.
InMode Ltd. (INMD) announced the expected release of its first-quarter 2023 financial results on May 2, 2023, before the Nasdaq market opens. Preliminary estimates indicate revenue between $105.7 million and $105.9 million, and non-GAAP earnings per diluted share in the range of $0.50 to $0.51. The company anticipates a non-GAAP gross margin between 83% and 85%. The management team will host a conference call at 8:30 a.m. Eastern Time to discuss the financial results. Investors are encouraged to register for the call ahead of time.
InMode Ltd. (NASDAQ: INMD) announced on March 13, 2023, that it does not hold cash or securities at Silicon Valley Bank. The company keeps its cash and non-insured deposits in U.S. money center banks and major Israeli financial institutions. Consequently, InMode does not anticipate any operational impact from the bank's closure. The company will continue to monitor potential effects on its suppliers, vendors, and other partners.
InMode is recognized for its innovative medical technologies, particularly those utilizing radiofrequency (RF) technology, serving various medical fields including plastic surgery and dermatology.
FAQ
What is the current stock price of InMode Ltd. Ordinary Shares (INMD)?
What is the market cap of InMode Ltd. Ordinary Shares (INMD)?
What products does InMode Ltd. offer?
What are InMode's core business categories?
Which markets does InMode serve?
How did InMode perform in Q3 2023?
What are some of InMode's flagship products?
What recent legal actions has InMode taken?
What new platforms has InMode recently announced?
Who is the new Chairman of InMode's Board?
What partnership has InMode recently entered into?
Where can I find more information about InMode?
